Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension

NARecruitingINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

September 5, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

March 30, 2026

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Ambrisentan

"Titration:~Monotherapy using ambrisentan will be initialized at a beginning dose of 5 mg (once daily). Drug intake is scheduled at the morning. After 4 weeks monitoring, the dose of ambrisentan will be uptitrated to 10 mg once daily. Otherwise, if intolerability is indicated, a dose of 5 mg (once daily) will be maintained through the study duration.~Maximum dose allowed: not to exceed 10 mg/day.~Administration:~Ambrisentan will be administered orally with or without food intake."

DRUG

Placebo

"Placebo tablet (one to two tablets corresponding to one to two verum tablets).~Administration:~Placebo will be administrated orally with or without food intake in the morning."

Trial Locations (1)

210006

RECRUITING

Nanjing First Hospital, Nanjing

All Listed Sponsors
collaborator

Tianjin Medical University General Hospital

OTHER

lead

Nanjing First Hospital, Nanjing Medical University

OTHER